Literature DB >> 24331893

An assessment of economic measures used in menorrhagia: a systematic review.

Sabina Sanghera1, Emma Frew2, Joe Kai3, Janesh Gupta4, Tracy Elizabeth Roberts2.   

Abstract

'Menorrhagia', or heavy menstrual bleeding, is a common problem affecting women. The principal driver for treatment is women's experience of its interference in their lives, so a measure of quality of life (QoL) is increasingly used as the primary outcome to assess treatment success. QoL measures need to accurately reflect women's concerns as these measures are often used to inform resource allocation decisions within the healthcare service. Healthcare decision-makers often advocate the use of generic measures so as to achieve consistency when making decisions. Generic measures, by definition, have a broad focus on QoL in contrast to disease-specific measures that focus on dimensions of health relevant to the condition. We report a systematic review of studies that have either used or assessed economic outcome measures in menorrhagia, and present criteria for assessing which measure is the most appropriate. Studies including women presenting with menorrhagia, and using or assessing economic measures were sought by searching nine electronic databases. Fifty-six eligible studies were identified. A narrative synthesis was most suitable to the review question. Eleven studies assessed the psychometric properties of the outcome measures, twelve studies applied the measures in an economic evaluation, and thirty-three used them in effectiveness studies. Mixed results on the psychometric properties of the instruments were observed. Studies were often found to include both a disease-specific and a generic measure. We found no consensus on the most appropriate economic outcome measure to use when assessing the cost-effectiveness of treatment for menorrhagia. This is an important finding as QoL is the primary focus for treatment decisions. The cyclical nature of the condition has a large impact on the reliability and validity of outcome measurement. Alternative measures, such as willingness-to-pay, which embrace more than health and avoid standard recall periods should be explored.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Heavy menstrual bleeding; Menorrhagia; Outcome measures; Quality of life; Utility

Mesh:

Year:  2013        PMID: 24331893     DOI: 10.1016/j.socscimed.2013.09.016

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  4 in total

1.  Levonorgestrel-releasing intrauterine system vs. usual medical treatment for menorrhagia: an economic evaluation alongside a randomised controlled trial.

Authors:  Sabina Sanghera; Tracy Elizabeth Roberts; Pelham Barton; Emma Frew; Jane Daniels; Lee Middleton; Laura Gennard; Joe Kai; Janesh Kumar Gupta
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

2.  Sensitivity to scale of willingness-to-pay within the context of menorrhagia.

Authors:  Sabina Sanghera; Emma Frew; Janesh Kumar Gupta; Joe Kai; Tracy Elizabeth Roberts
Journal:  Health Expect       Date:  2016-02-23       Impact factor: 3.377

3.  Exploring the Use of Cost-Benefit Analysis to Compare Pharmaceutical Treatments for Menorrhagia.

Authors:  Sabina Sanghera; Emma Frew; Janesh Kumar Gupta; Joe Kai; Tracy Elizabeth Roberts
Journal:  Pharmacoeconomics       Date:  2015-09       Impact factor: 4.981

Review 4.  What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews.

Authors:  Aureliano Paolo Finch; John Edward Brazier; Clara Mukuria
Journal:  Eur J Health Econ       Date:  2017-05-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.